Clinical study on anti-leukemia effect mediated by dentritic cells

Immunotherapy of tumor is extensively attentioned as an important part of combined therapy of tumor in recent years. Dendritic cell (DC) is the most powerful antigen presenting cell (APC) by now which not only activates auto-immunity to attack tumor cells, but also does help to enhance antitumor eff...

Full description

Saved in:
Bibliographic Details
Published inZhongguo shi yan xue ye xue za zhi Vol. 13; no. 3; p. 412
Main Authors Chen, Hu, Lou, Xiao, Jiang, Min, Hu, Liang-Ding, Yu, Zhi-Yong, Xu, Chen, Li, Bo-Tao, Ning, Hong-Mei, Li, Yu-Hang, Feng, Kai, Liu, Guang-Xian
Format Journal Article
LanguageChinese
Published China 01.06.2005
Subjects
Adolescent
Adult
Bone Marrow Transplantation
Cells, Cultured
Combined Modality Therapy
Dendritic Cells - cytology
Dendritic Cells - immunology
Dendritic Cells - transplantation
Female
Flow Cytometry
Humans
Immunotherapy, Adoptive
Kaplan-Meier Estimate
Leukemia, Monocytic, Acute - immunology
Leukemia, Monocytic, Acute - pathology
Leukemia, Monocytic, Acute - therapy
Leukemia, Myeloid, Acute - immunology
Leukemia, Myeloid, Acute - pathology
Leukemia, Myeloid, Acute - therapy
Leukemia, Myelomonocytic, Acute - immunology
Leukemia, Myelomonocytic, Acute - pathology
Leukemia, Myelomonocytic, Acute - therapy
Male
Middle Aged
Online AccessGet more information

Cover

More Information
Summary:Immunotherapy of tumor is extensively attentioned as an important part of combined therapy of tumor in recent years. Dendritic cell (DC) is the most powerful antigen presenting cell (APC) by now which not only activates auto-immunity to attack tumor cells, but also does help to enhance antitumor effect for allogenic bodies. To explore the feasibility and safety of clinical therapy application of peripheral blood derived DC cultured ex vivo, and analyze the influence of DC-inducing-immunotherapy upon long-term survival of ANLL patients accepted autologous bone marrow transplantation, peripheral blood mononuclear cells (PBMNC) of 13 ANLL patients after autologous bone marrow transplantation were collected by using CS3000Plus. DC immunotherapy was administered after cultivation of PBMNC ex vivo for 2 weeks, desease-free survival time was observed after therapy for long time follow-up. The results showed that no any severe adverse event associated with DC therapy was observed, the survival analysis of Kaplan-Meie
ISSN:1009-2137